Simplify Asset Management Inc. Buys 25,456 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Simplify Asset Management Inc. lifted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 20.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,641 shares of the company’s stock after acquiring an additional 25,456 shares during the quarter. Simplify Asset Management Inc. owned approximately 0.17% of Syndax Pharmaceuticals worth $1,952,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. KLP Kapitalforvaltning AS bought a new stake in Syndax Pharmaceuticals in the 4th quarter worth about $219,000. Teacher Retirement System of Texas boosted its stake in shares of Syndax Pharmaceuticals by 18.7% in the 4th quarter. Teacher Retirement System of Texas now owns 22,769 shares of the company’s stock worth $301,000 after buying an additional 3,585 shares during the last quarter. AlphaQuest LLC grew its holdings in shares of Syndax Pharmaceuticals by 32.3% in the fourth quarter. AlphaQuest LLC now owns 23,623 shares of the company’s stock valued at $312,000 after acquiring an additional 5,765 shares in the last quarter. E Fund Management Co. Ltd. increased its position in shares of Syndax Pharmaceuticals by 14.4% during the fourth quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company’s stock valued at $167,000 after acquiring an additional 1,583 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Syndax Pharmaceuticals by 1.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 704,823 shares of the company’s stock worth $9,318,000 after acquiring an additional 8,876 shares during the period.

Insider Transactions at Syndax Pharmaceuticals

In related news, insider Neil Gallagher sold 4,618 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the sale, the insider now owns 85,095 shares in the company, valued at approximately $1,318,972.50. This trade represents a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Keith A. Goldan sold 3,777 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $58,543.50. Following the sale, the chief financial officer now directly owns 90,746 shares of the company’s stock, valued at $1,406,563. This represents a 4.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,683 shares of company stock valued at $336,087. 4.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on SNDX. Citigroup decreased their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. StockNews.com lowered shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 23rd. Scotiabank dropped their target price on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. HC Wainwright restated a “buy” rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Finally, JPMorgan Chase & Co. upped their price objective on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $36.20.

Syndax Pharmaceuticals Price Performance

NASDAQ:SNDX opened at $13.71 on Friday. Syndax Pharmaceuticals, Inc. has a 1 year low of $12.06 and a 1 year high of $25.07. The stock’s fifty day moving average price is $14.24 and its two-hundred day moving average price is $16.08. The company has a market cap of $1.18 billion, a P/E ratio of -3.78 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The company had revenue of $7.68 million during the quarter, compared to analyst estimates of $86.32 million. On average, analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).